Published in Eur J Surg Oncol on June 01, 1992
Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol (2009) 2.11
Dermatofibrosarcoma protuberans with fibrosarcomatous transformation of the head and neck. Head Neck Oncol (2011) 1.48
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol (2010) 1.48
Dermatofibrosarcoma protuberans treated by micrographic surgery. Br J Cancer (2002) 1.07
Imatinib in the treatment of dermatofibrosarcoma protuberans. Biologics (2007) 1.07
Dermatofibrosarcoma presenting as a nodule in the breast of a 75-year-old woman: a case report. J Med Case Rep (2011) 1.07
Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans. Sarcoma (2011) 1.01
Reconstructive challenge of dermatofibrosarcoma protuberans in the female breast. World J Surg Oncol (2011) 1.00
Atrophic dermatofibrosarcoma protuberans. J Dermatol Case Rep (2012) 0.99
Dermatofibrosarcoma protuberans: Our experience of 59 cases. Oncol Lett (2012) 0.98
Dermatofibrosarcoma protuberans of scalp with cervical lymph node metastasis. Sarcoma (2004) 0.98
Considerations for tissue expansion in the management of massive dermatofibrosarcoma protuberans of the head and neck. Eplasty (2013) 0.95
Dermatofibrosarcoma protuberans: Role of wide local excision. South Asian J Cancer (2013) 0.94
Wide Local Excision for Dermatofibrosarcoma Protuberans: A Single-Center Series of 90 Patients. Biomed Res Int (2015) 0.87
Dermatofibrosarcoma protuberans: from translocation to targeted therapy. Cancer Biol Med (2015) 0.82
Status report on the management of dermatofibrosarcoma protuberans: is there a viable role for the use of imatinib mesylate? In which cases may it be therapeutically helpful and in which cases not? J Clin Aesthet Dermatol (2011) 0.81
Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients. Medicine (Baltimore) (2015) 0.80
Dermatofibrosarcoma protuberans: A rare cutaneous tumour. J Surg Case Rep (2012) 0.78
Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib. World J Surg Oncol (2013) 0.78
Dermatofibrosarcoma protuberans: a study of clinical, pathologic, genetic, and therapeutic features in Korean patients. Yonsei Med J (2015) 0.77
Malignant skin lesions in Oshogbo, Nigeria. Pan Afr Med J (2015) 0.75
Indication guidelines for Mohs micrographic surgery in skin tumors. An Bras Dermatol (2016) 0.75
Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Mol Clin Oncol (2017) 0.75
[Dermatofibrosarcoma protuberans: report of 38 cases]. Pan Afr Med J (2014) 0.75
Dermatofibrosarcoma protuberans, a rare but locally aggressive tumor on finger: clinical and aeromedical considerations. Case Reports Plast Surg Hand Surg (2015) 0.75
Advances in the systemic treatment of cutaneous sarcomas. Semin Oncol (2012) 0.75
Dermatofibrosarcoma protuberans at an uncommon site. Indian J Dermatol (2014) 0.75
Giant ulcerative dermatofibroma. Case Rep Otolaryngol (2013) 0.75
Dermatofibrosarcoma: a rare neoplasm of skin. BMJ Case Rep (2012) 0.75
Dermatofibrosarcoma Protuberans-Like Tumor With COL1A1 Copy Number Gain in the Absence of t(17;22). Am J Dermatopathol (2016) 0.75
Dermatofibrosarcoma Protuberans. Curr Treat Options Oncol (2017) 0.75
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol (1996) 2.61
Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy. J Am Coll Surg (2001) 1.79
Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg (2000) 1.71
Positive iliac and obturator nodes in melanoma: survival and prognostic factors. Ann Surg Oncol (1999) 1.55
Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg (1996) 1.54
Lymph node metastasis from melanoma with an unknown primary site. Br J Surg (1990) 1.49
Clear cell sarcoma (malignant melanoma) of soft parts: A clinicopathologic study of 30 cases. Cancer (1999) 1.46
[Identification of the sentinel node in patients with breast carcinoma]. Ned Tijdschr Geneeskd (1996) 1.42
Evaluation of mammary lymphoscintigraphy by a single intratumoral injection for sentinel node identification. J Nucl Med (2000) 1.25
Resectable retroperitoneal soft tissue sarcomas. The effect of extent of resection and postoperative radiation therapy on local tumor control. Cancer (1994) 1.25
Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery (1994) 1.23
Frozen section investigation of the sentinel node in malignant melanoma and breast cancer. Ann Surg Oncol (2001) 1.19
The definition of a sentinel node. Ann Surg Oncol (2001) 1.15
Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol (1997) 1.13
Vulvar sarcoma: clinical implications. Eur J Obstet Gynecol Reprod Biol (1994) 1.13
Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol (1988) 1.10
Myosin and myoglobin as tumor markers in the diagnosis of rhabdomyosarcoma. A comparative study. Am J Surg Pathol (1984) 1.07
Surgery for melanoma metastatic to the gastrointestinal tract. Br J Surg (1990) 1.06
History of sentinel node and validation of the technique. Breast Cancer Res (2001) 1.05
Single intralesional tracer dose for radio-guided excision of clinically occult breast cancer and sentinel node. Ann Surg Oncol (2001) 1.04
Grading of soft tissue sarcomas: experience of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (1993) 1.03
Regional lymph node metastases in patients with soft tissue sarcomas of the extremities, what are the therapeutic consequences? Eur J Surg Oncol (1988) 1.01
Follow-up after treatment of primary breast cancer. Br J Surg (1989) 1.01
VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J Pathol (1995) 0.98
Pleomorphic rhabdomyosarcoma in adults: immunohistochemistry as a tool for its diagnosis. Hum Pathol (1987) 0.98
Lymphatic mapping and sentinel lymph node biopsy in breast cancer. Eur J Nucl Med (1999) 0.97
Vascular complications of isolated limb perfusion. Eur J Surg Oncol (1998) 0.97
Altered lymphatic drainage after lymphadenectomy or radiotherapy of the axilla in patients with breast cancer. Br J Surg (1996) 0.97
Reliability of lymphoscintigraphy in indicating the number of sentinel nodes in melanoma patients. Ann Surg Oncol (2000) 0.96
Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg (1995) 0.96
Sentinel node biopsy for melanoma in the head and neck region. Head Neck (2000) 0.96
Sentinel nodes outside lymph node basins in patients with melanoma. Br J Surg (2001) 0.93
Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma. Melanoma Res (1995) 0.93
Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer (1994) 0.91
Epithelioid sarcoma. Eur J Surg Oncol (1989) 0.90
Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg (1999) 0.90
Identification and biopsy of the sentinel lymph node in breast cancer. Eur J Surg Oncol (1998) 0.90
Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer (1989) 0.90
Creatine kinase subunits M and B as markers in the diagnosis of poorly differentiated rhabdomyosarcomas in children. Hum Pathol (1985) 0.90
Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg (1996) 0.90
Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol (1999) 0.89
Lymphatic mapping with intralesional tracer administration in breast carcinoma patients. Cancer (2000) 0.89
Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors. J Surg Oncol (1997) 0.88
Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol (1998) 0.88
Limb-sparing therapy of extremity soft tissue sarcomas: treatment outcome and long-term functional results. Eur J Cancer (1994) 0.88
Skeletal muscle actin as tumor marker in the diagnosis of rhabdomyosarcoma in childhood. Am J Surg Pathol (1985) 0.87
Improved sentinel node visualization in breast cancer by optimizing the colloid particle concentration and tracer dosage. Nucl Med Commun (2001) 0.87
Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res (1994) 0.86
Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan. Eur J Surg Oncol (1999) 0.86
Lymph node metastases in the neck and parotid gland from an unknown primary melanoma. Clin Otolaryngol Allied Sci (1994) 0.86
Isolated limb perfusion with high-dose tumor necrosis factor-alpha for locally advanced extremity soft tissue sarcomas. Cancer Treat Res (1997) 0.85
Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg (1999) 0.85
Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg (1994) 0.85
Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs. Anticancer Res (1987) 0.85
A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities. Eur J Cancer (1995) 0.85
Is lymphatic mapping in breast cancer adequate and safe? World J Surg (2001) 0.84
Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone. Eur J Surg Oncol (2001) 0.84
Technique of sentinel node biopsy in breast cancer. Eur J Surg Oncol (1998) 0.84
Lymphoscintigraphy in oncology: a rediscovered challenge. Eur J Nucl Med (1999) 0.83
Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg (1994) 0.83
Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone. Cancer Chemother Pharmacol (1992) 0.83
Systemic leakage during isolated limb perfusion for melanoma. Br J Surg (1993) 0.83
Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol (1998) 0.82
False negative sentinel node procedure established through palpation of the biopsy wound. Eur J Surg Oncol (2000) 0.82
Reproducibility of lymphoscintigraphy for lymphatic mapping in cutaneous melanoma. J Nucl Med (1996) 0.82
Validation of gamma probe detection of the sentinel node in melanoma. J Nucl Med (1997) 0.81
Low risk of locoregional recurrence of primary breast carcinoma after treatment with a modification of the Halsted radical mastectomy and selective use of radiotherapy. Cancer (1999) 0.81
Sensitivity of sentinel node biopsy in melanoma. J Surg Oncol (2001) 0.81
Characterization of two cell lines, derived from two malignant fibrous histiocytomas. J Pathol (1986) 0.81
Results of radical dissection of the groin in patients with stage II melanoma and histologically proved metastases of the iliac or obturator lymph nodes, or both. Surg Gynecol Obstet (1988) 0.81
[Characteristics of patients with recurrence of primary melanoma at least 10 years following surgical treatment]. Ned Tijdschr Geneeskd (1994) 0.80
Is there an indication for a double perfusion schedule with melphalan for patients with recurrent melanoma of the limbs? Melanoma Res (1994) 0.80
The impact of the CUSA ultrasonic dissection device on major liver resections. Neth J Surg (1991) 0.80
Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas. Semin Oncol (1997) 0.79
[Revised consensus melanoma of the skin]. Ned Tijdschr Geneeskd (1990) 0.79
Physiological implications of hyperbaric oxygen tensions in isolated limb perfusion using melphalan: a pilot study. Eur Surg Res (1996) 0.78
Comparison between the use of whole blood versus a diluted perfusate in regional isolated perfusion by continuous monitoring of transcutaneous oxygen tension: a pilot study. J Invest Surg (1994) 0.78
The value of Cloquet's node in predicting melanoma nodal metastases in the pelvic lymph node basin. Ann Surg Oncol (2001) 0.78
Results of regional isolated perfusion for locally inoperable melanoma of the limbs. Melanoma Res (1994) 0.78
Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eur J Surg Oncol (1996) 0.78
To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater. J Clin Oncol (1988) 0.78
Improved staging of breast cancer through lymphatic mapping and sentinel node biopsy. Eur J Surg Oncol (1998) 0.78
Controversies concerning adjuvant regional isolated perfusion for stage I melanoma of the extremities. World J Surg (1992) 0.77
[Alveolar soft tissue sarcoma]. Ned Tijdschr Geneeskd (1981) 0.77
Malignant schwannoma with a rhabdomyoblastic component, a so-called triton tumor. A clinicopathologic study. Cancer (1986) 0.77
Hyperthermic isolated limb perfusion for the treatment of soft tissue sarcomas. Semin Surg Oncol (1998) 0.77
Value of laboratory tests in monitoring acute regional toxicity after isolated limb perfusion. Ann Surg Oncol (1997) 0.77
Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities. Radiother Oncol (1998) 0.77
Surgical intervention for complications caused by late radiation damage of the small bowel: a retrospective analysis. Eur J Surg Oncol (1993) 0.77
Report of a symposium on diagnosis and treatment of adult soft tissue sarcomas in the head and neck. Eur J Surg Oncol (1995) 0.77